Biontech Se (BNTX) - News Archive

New York & Mainz, Germany Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) have announced a significant milestone in the fight against COVID-19, as the U.S. Food and Drug Administration (FDA) has officially approv...

In a significant development for the biopharmaceutical landscape, BioNTech SE (Nasdaq: BNTX) has announced that Ryan Richardson, the company’s Chief Strategy Officer, will vacate his position on the Management Board eff...

MAINZ and TÜBINGEN, Germany, June 12, 2025 In a groundbreaking development within the global biotechnology landscape, BioNTech SE (Nasdaq: BNTX) and CureVac N.V. (Nasdaq: CVAC) have jointly announced a strategic agreeme...

BioNTech Forms Strategic Alliance with CureVac: A New Era for mRNA TherapeuticsMAINZ and Tübingen, Germany, June 12, 2025 — In a landmark move that underscores the increasing significance of mRNA technology in modern me...

In a proactive move to enhance its oncology strategy, BioNTech SE has announced its decision to acquire Biotheus, a company known for its innovative therapeutic approaches in cancer treatment. This acquisition comes at...

BioNTech Reports Dynamic Financial Performance for Q3 2024: A Glimpse into Future Innovations in Immunotherapy BioNTech SE, a trailblazer in the biotechnology landscape, has revealed robust financial results for the thi...

LONDON, United Kingdom, October 1, 2024 In a landmark event that demonstrated the tremendous potential of artificial intelligence (AI) in revolutionizing the biomedical landscape, BioNTech SE alongside its AI subsidiary...

: The capacitive sensors market is poised for significant expansion, projected to reach a value of USD 48.05 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.9%. This surge in value is predominantly...

On October 1, 2024, BioNTech SE (NASDAQ: BNTX) is set to showcase its commitment to cutting-edge science by hosting an AI Day as part of its ongoing Innovation Series. This event promises to be a vital platform for disc...

BioNTech SE (Nasdaq: BNTX), renowned for its pioneering mRNA technology and its significant role in combating the COVID-19 pandemic, is poised to make a major impact on the oncology landscape with its forthcoming presen...

Tempus Announces Real-World Data Collaboration with BioNTech CHICAGO - Tempus AI, Inc. (NASDAQ: TEM, Tempus), a forefront technology company spearheading the adoption of artificial intelligence (AI) to enhance precision...

In an era wherein the evolution of the COVID-19 virus continues to pose challenges to global public health, pharmaceutical leaders Pfizer Inc. and BioNTech SE have again demonstrated their commitment to combating this o...

In a significant development in the ongoing fight against COVID-19, Pfizer Inc. and BioNTech SE have achieved a major milestone with the approval of their Omicron KP.2-adapted COVID-19 vaccine by the U.S. Food and Drug...

In the recent interim report for H1 2024, BioNTech SE has revealed a notable decline in its return on average invested assets (ROI), registering at 4.44% for the fourth quarter of 2023. This figure is markedly below the...

BioNTech Reports Second Quarter 2024 Results and Provides Corporate Update BioNTech SE (Nasdaq: BNTX), a prominent player in the biotechnology sector, recently announced its financial results for the second quarter of 2...

BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024MAINZ, Germany, July 22, 2024 - BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) has announced that it will be releasing...

In a significant development, Pfizer Inc. and BioNTech SE have received positive news for their Omicron JN.1-adapted COVID-19 vaccine. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

MAINZ, Germany and SHANGHAI, China June 24, 2024 BioNTech SE (Nasdaq: BNTX, BioNTech) and Duality Biologics (Suzhou) Co., Ltd. (DualityBio) have announced that the U.S. Food and Drug Administration (FDA) has granted Fas...

Investigational Acasunlimab (DuoBody -PD-L1x4-1BB) in Combination with Pembrolizumab Shows Promising Results in Phase 2 Trial for Previously Treated Metastatic Non-small Cell Lung CancerCOPENHAGEN, Denmark, and MAINZ, G...

BioNTech SE is set to shine at this year s American Society of Clinical Oncology (ASCO) Annual Meeting as it presents groundbreaking clinical trial data for select programs from its diversified immuno-oncology pipeline....